Schering-Plough names communications directorSchering-Plough named Pfizer's Catherine Cantone director, global product communications and advocacy relations.
Cantone, formerly director of public relations at Pfizer, reports to vice president of global product communications and advocacy development Mary-Frances Faraji, herself a Pfizer alum. She will be responsible for global product communications and advocacy on Schering-Plough's arthritis treatment Remicade, as well as the company's oncology franchise. Cantone replaces Joy Schmitt, who is moving abroad.
The oncology franchise includes Temodar, for brain cancer, and Intron, for renal cell carcinoma, in the US. The firm also markets Caelyx, for ovarian cancer, Kaposi's sarcoma and metastatic breast cancer, outside the US.
Remicade posted strong growth in the second quarter, with revenues rising 31% to $307 million, contributing to an overall 11% gain, year-on-year. The drug recently won EU approval as a monotherapy in the treatment of psoriatic arthritis.
“We're very pleased to have someone of Cathy's caliber to support these important areas,” said Faraji.
Cantone came to Pfizer through Pharmacia, where she was senior manager of public relations and advocacy development, and had previously worked for Makovsky and Company and the Leukemia Society of America. She is a board member of CancerCare New Jersey and a member of the Healthcare Businesswomen's Association.